⌕
Disc Medicine · IRON · Nasdaq
Tenet 49 · Mixed
Compare
$76.57−0.03%At closeTenet 49 · Mixed
$76.57−0.02 (−0.03%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Disc Medicine (IRON) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+58.2%) and Capex step-up ($933.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼94.0%
−212.2
FY21→FY25CAGR —
Free cash flow ($M)▼92.0%
−181.3
capex stepped upCAGR —
Diluted EPS▼51.8%
−6.01
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+58.2%

22.3mn → 35.3mn diluted shares since FY23. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$933.0K

▲85% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−170.6R&D−65.4SG&A−236.0Op income23.8Tax & other−212.2Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
183,141.0170,640.096,671.069,264.033,437.025,170.0▲76.5%+61.4%
Selling, general & admin
82,589.065,382.033,049.021,861.014,038.05,763.0▲97.8%+83.5%
Total operating expenses
265,730.0236,022.0129,720.091,125.047,475.030,933.0▲81.9%+66.2%
Operating incomefeeds ROC rank
−265,730.0−236,022.0−129,720.0−91,125.0−47,475.0−30,933.0▼81.9%—
Other income, net
22,945.024,199.020,718.014,795.0648.0−5,036.0——
Pretax income
−242,785.0−211,823.0−109,002.0−76,330.0−46,827.0−35,969.0▼94.3%—
Income tax
317.0361.0355.099.00.0—▲1.7%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−243,102.0−212,184.0−109,357.0−76,429.0−46,827.0−35,969.0▼94.0%—
Per share
Diluted EPSbuyback-sensitive
−6.36−6.01−3.96−3.42−45.05−40.95▼51.8%—
Diluted shares (mn)
38.9035.3027.6122.321.040.88▲27.9%+151.8%
Margins
† TTM = trailing four quarters through 2026-09-30.
FY20 – FY20 · 1 more year
Unlock the full history →
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.